西米普明与特拉匹韦三联疗法治疗慢性丙型肝炎病毒感染对既往聚乙二醇干扰素/利巴韦林治疗无应答者患者报告结局的影响：III期ATTAIN研究结果 - Suppr

Suppr

超能文献

Impact of Simeprevir Versus Telaprevir Triple Therapy for Chronic Hcv Infection on Patient-Reported Outcomes in Prior Non-Responders to Peginterferon/Ribavirin Results from the Phase Iii Attain Study.

作者信息

Scott J, Corbett C, Gilles L, Wan G, Sbarigia U, Jessner W

机构信息

Janssen Global Services, LLC, High Wycombe, UK.

Janssen Research and Development, Beerse, Belgium.

出版信息

Value Health. 2014 Nov;17(7):A682. doi: 10.1016/j.jval.2014.08.2543. Epub 2014 Oct 26.

DOI:10.1016/j.jval.2014.08.2543

PMID:27202521

Abstract

摘要

相似文献

Impact of Simeprevir Versus Telaprevir Triple Therapy for Chronic Hcv Infection on Patient-Reported Outcomes in Prior Non-Responders to Peginterferon/Ribavirin Results from the Phase Iii Attain Study.

Value Health. 2014 Nov;17(7):A682. doi: 10.1016/j.jval.2014.08.2543. Epub 2014 Oct 26.

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.

J Med Virol. 2013 Oct;85(10):1746-53. doi: 10.1002/jmv.23673. Epub 2013 Jul 16.

Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.

Clin Ther. 2015 Feb 1;37(2):243-67. doi: 10.1016/j.clinthera.2014.12.012. Epub 2015 Jan 16.

Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.

J Med Virol. 2012 Jul;84(7):1097-105. doi: 10.1002/jmv.23262.

Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.

J Med Econ. 2015;18(7):502-11. doi: 10.3111/13696998.2015.1029492. Epub 2015 Mar 31.

Telaprevir: a hepatitis C NS3/4A protease inhibitor.

Clin Ther. 2012 Sep;34(9):1857-82. doi: 10.1016/j.clinthera.2012.07.011. Epub 2012 Aug 28.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.

J Viral Hepat. 2015 Apr;22(4):366-75. doi: 10.1111/jvh.12346. Epub 2014 Nov 3.

Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b.

J Med Virol. 2015 Apr;87(4):609-18. doi: 10.1002/jmv.24113.

Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.

J Hepatol. 2012 Feb;56(2):455-63. doi: 10.1016/j.jhep.2011.08.006. Epub 2011 Aug 30.

引用本文的文献

Direct-acting antivirals for chronic hepatitis C.

Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012143. doi: 10.1002/14651858.CD012143.pub3.

Direct-acting antivirals for chronic hepatitis C.

Cochrane Database Syst Rev. 2017 Jun 6;6(6):CD012143. doi: 10.1002/14651858.CD012143.pub2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Impact of Simeprevir Versus Telaprevir Triple Therapy for Chronic Hcv Infection on Patient-Reported Outcomes in Prior Non-Responders to Peginterferon/Ribavirin Results from the Phase Iii Attain Study.

作者信息

Scott J, Corbett C, Gilles L, Wan G, Sbarigia U, Jessner W

机构信息

Janssen Global Services, LLC, High Wycombe, UK.

Janssen Research and Development, Beerse, Belgium.

出版信息

Value Health. 2014 Nov;17(7):A682. doi: 10.1016/j.jval.2014.08.2543. Epub 2014 Oct 26.

DOI:10.1016/j.jval.2014.08.2543

PMID:27202521

Abstract

摘要

相似文献

Value Health. 2014 Nov;17(7):A682. doi: 10.1016/j.jval.2014.08.2543. Epub 2014 Oct 26.

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.

J Med Virol. 2013 Oct;85(10):1746-53. doi: 10.1002/jmv.23673. Epub 2013 Jul 16.

Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.

Clin Ther. 2015 Feb 1;37(2):243-67. doi: 10.1016/j.clinthera.2014.12.012. Epub 2015 Jan 16.

Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.

J Med Virol. 2012 Jul;84(7):1097-105. doi: 10.1002/jmv.23262.

Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.

J Med Econ. 2015;18(7):502-11. doi: 10.3111/13696998.2015.1029492. Epub 2015 Mar 31.

Telaprevir: a hepatitis C NS3/4A protease inhibitor.

Clin Ther. 2012 Sep;34(9):1857-82. doi: 10.1016/j.clinthera.2012.07.011. Epub 2012 Aug 28.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.

J Viral Hepat. 2015 Apr;22(4):366-75. doi: 10.1111/jvh.12346. Epub 2014 Nov 3.

Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b.

J Med Virol. 2015 Apr;87(4):609-18. doi: 10.1002/jmv.24113.

Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.

J Hepatol. 2012 Feb;56(2):455-63. doi: 10.1016/j.jhep.2011.08.006. Epub 2011 Aug 30.

引用本文的文献

Direct-acting antivirals for chronic hepatitis C.

Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012143. doi: 10.1002/14651858.CD012143.pub3.

Direct-acting antivirals for chronic hepatitis C.

Cochrane Database Syst Rev. 2017 Jun 6;6(6):CD012143. doi: 10.1002/14651858.CD012143.pub2.